A. Novotná

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

W. Notcutt, J. Mareš, R. Langford, 2013, Journal of Neurology.

Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report

E. Ehler, P. Jansa, A. Novotná, 2016 .

Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B‐cell chronic lymphocytic leukaemia

M. Arenbergerova, P. Arenberger, T. Jirásek, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis

C. Pozzilli, X. Montalban, G. Comi, 2011, European journal of neurology.

A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis

J. Mareš, M. Vachová, R. Taláb, 2014 .